The global breast biopsy market size was valued at USD 2.83 billion in 2025 and is projected to grow from USD 3.14 billion in 2026 to USD 7.12 billion by 2034, registering a CAGR of 10.8% during the forecast period from 2026 to 2034. North America dominated the breast biopsy market with a market share of 38.6% in 2025.
A breast biopsy is a diagnostic procedure used to remove a small sample of breast tissue or cells for laboratory examination to determine whether an abnormal area is benign or cancerous. It may be performed using fine-needle aspiration, core needle biopsy, vacuum-assisted biopsy, or surgical methods. Breast biopsies play an important role in confirming breast cancer diagnoses and guiding appropriate treatment decisions.
Download a Free Sample To learn more about this report,
Tomosynthesis-Guided Vacuum Biopsy Improves Lesion Targeting
Breast biopsy market analysis shows that wider use of digital breast tomosynthesis is shifting biopsy procedures toward tomosynthesis-guided vacuum sampling for lesions that are difficult to identify with conventional imaging. A September 2025 meta-analysis of 1,361 tomosynthesis-only architectural distortion lesions found a 37% pooled malignancy rate, supporting tissue sampling of these findings. This transition improves access to targeted biopsy for subtle architectural distortions that may not have a clear ultrasound correlate.
MRI-Guided Vacuum Biopsy Expands Diagnosis of MRI-Only Lesions
Identification of suspicious lesions visible only on breast MRI is shifting biopsy systems toward MRI-guided vacuum-assisted procedures that can obtain tissue from otherwise difficult-to-target sites. A 2026 study of 292 MRI-only lesions reported a 28.4% malignancy rate, while histopathological discordance occurred in 6.5% of cases. This transition expands tissue diagnosis for MRI-detected abnormalities while reinforcing the role of radiologic-pathologic concordance after biopsy.
Breast Cancer Screening and Ultrasound-Guided Biopsy Expansion Drive Market
Breast cancer screening identifies suspicious abnormalities that may require tissue sampling for definitive diagnosis, creating a direct increase in demand for biopsy procedures. The NCI notes that suspicious or highly suspicious mammography findings may require biopsy as part of the diagnostic pathway. This screening-to-biopsy pathway supports continued use of core needle, vacuum-assisted, and other biopsy methods. Wider screening activity therefore expands the patient base requiring breast biopsy services.
Ultrasound-guided procedures provide real-time visualization of breast abnormalities and allow radiologists to guide needles directly into suspicious masses. Current RadiologyInfo guidance identifies core needle and vacuum-assisted devices as established applications for ultrasound-guided breast biopsy. The use of these procedures across palpable masses, solid lesions, and abnormal tissue changes expands applications for biopsy needles and associated equipment. This broader clinical use strengthens demand for ultrasound-compatible biopsy devices.
Breast Radiologist Shortages and Limited Imaging Infrastructure Restrain Market Expansion
Limited availability of trained breast radiologists can reduce the capacity of healthcare facilities to perform image-guided biopsy procedures, especially where diagnostic workloads are high. Accurate lesion assessment and biopsy guidance require specialized clinical expertise, making staffing gaps a direct constraint on procedure availability. This shortage can extend waiting times and slow the adoption of advanced breast biopsy technologies.
Uneven availability of mammography, ultrasound, MRI, and biopsy-support equipment can restrict access to image-guided diagnostic procedures across healthcare facilities. Rural and lower-resource settings may lack the infrastructure needed to identify and accurately target suspicious breast lesions. Such infrastructure gaps can reduce procedure volumes and constrain breast biopsy market penetration across underserved regions.
AI-Assisted Pathology and Digital Specimen Management Offer Growth Opportunities
Pathology technology providers and biopsy equipment companies can integrate AI-assisted tissue analysis with biopsy workflows to support biomarker assessment and diagnostic review. PathAI, for example, expanded its digital pathology ecosystem in 2025 through partnerships covering breast cancer biomarkers and prognostic analysis. Such integrations can create revenue through software subscriptions, diagnostic modules, and workflow solutions, contributing to breast biopsy market growth.
Hospitals, pathology laboratories, and diagnostic technology providers can develop digital systems for biopsy specimen tracking, slide management, remote review, and laboratory workflow coordination. A 2025 study involving Tata Memorial Hospital demonstrated that digital pathology reduced turnaround time and costs in breast cancer HER2 testing by enabling remote slide sharing. These solutions can generate recurring revenue through software licensing, workflow platforms, and laboratory integration services.
Biopsy Device Supply Disruptions and Radiologic-Pathologic Discordance Hinder Growth
Supply interruptions for specialized biopsy needles can create procurement uncertainty for hospitals and device suppliers, affecting scheduled procedures and inventory planning. In June 2026, the FDA reported an ongoing U.S. shortage of stereotactic breast biopsy needles, with the disruption expected to extend through March 2027. Such shortages can delay procedures, increase inventory-management costs, and make market expansion more difficult for device manufacturers and healthcare providers.
Differences between imaging findings and biopsy results can require additional sampling or surgical assessment, adding complexity to the diagnostic pathway. A 2025 consensus document recommends repeat biopsy when benign histology does not adequately explain suspicious imaging findings, while a 2026 systematic review reported clinically meaningful malignancy-upgrade risks in discordant cases. These additional procedures can increase healthcare costs and make providers more cautious about adopting new biopsy technologies.
The biopsy needle segment accounted for a share of 29.4% in 2025, due to their precise tissue sampling capability, minimally invasive design, ease of use, and widespread application in breast lesion diagnosis.
The guidance systems segment is expected to grow at a CAGR of 8.11% during the forecast period 2026-2034, driven by improved biopsy precision, enhanced lesion targeting, real-time procedural guidance, and greater adoption of advanced imaging-assisted biopsy techniques. The biopsy forceps, needle-based biopsy guns, localization wires, and other guidance techniques segments are also expected to support market growth through their use in accurate tissue sampling, lesion localization, and image-guided breast biopsy procedures.
Request Customizationto receive a tailored report.
The core needle biopsy (CNB) segment accounted for a share of 32.8% in 2025, owing to its ability to obtain larger tissue samples, provide reliable histopathological evaluation, and support accurate diagnosis of suspicious breast lesions.
The liquid breast biopsy segment is expected to grow at a CAGR of 10.36% during the forecast period 2026-2034, fueled by its minimally invasive approach, ability to detect circulating biomarkers, and potential for repeated monitoring of breast cancer-related molecular changes. The Fine-Needle Aspiration Biopsy (FNAB), Vacuum-Assisted Breast Biopsy (VABB), Excisional and Incisional Breast Biopsy, and Open Surgical Breast Biopsy segments are also expected to support market growth through their use across different lesion characteristics, diagnostic requirements, and clinical settings.
The image-guided biopsy segment accounted for a share of 88.3% in 2025, supported by its ability to provide precise lesion localization, improve sampling accuracy, and enable effective biopsy procedures through real-time imaging guidance.
The liquid biopsy segment is expected to grow at a CAGR of 10.18% during the forecast period 2026-2034, propelled by its minimally invasive approach, potential for repeated testing, and ability to support biomarker-based cancer detection and monitoring.
The early cancer screening segment accounted for a share of 49.5% in 2025, due to the importance of early detection in identifying suspicious breast lesions, supporting timely diagnosis, and improving treatment planning.
The recurrence monitoring segment is expected to grow at a CAGR of 8.49% during the forecast period 2026-2034, driven by the need for regular disease assessment, early identification of recurrent cancer, and improved clinical decision-making during follow-up care. The therapy selection and treatment monitoring segments are also expected to support market growth through their role in guiding personalized treatment decisions and evaluating patient response to therapy.
The hospitals and surgical centers segment accounted for a share of 51.6% in 2025, owing to their advanced diagnostic infrastructure, availability of specialized healthcare professionals, and capacity to perform biopsy procedures alongside comprehensive breast cancer diagnosis and treatment services.
The breast care centers segment is expected to grow at a CAGR of 8.06% during the forecast period 2026-2034, fueled by specialized breast health services, integrated diagnostic capabilities, patient-focused care, and greater access to dedicated breast cancer screening and biopsy procedures. The imaging and diagnostic centers segment is also expected to support market growth through specialized imaging facilities, diagnostic expertise, and wider access to breast lesion evaluation and biopsy services.
Speak to an Analystto discuss market opportunities.
The North America breast biopsy market accounted for the largest regional share of 38.6% in 2025, while the U.S. is estimated to record 321,910 new female breast cancer cases in 2026, reinforcing the need for diagnostic procedures following abnormal screening results.
The U.S. breast biopsy market is supported by the projected 321,910 female breast cancer cases in 2026, while the Canada breast biopsy market is supported by an estimated 32,400 new female breast cancer cases in 2026, representing 26% of all new cancer cases among Canadian women.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific breast biopsy market is expected to grow at a CAGR of 9.18% during the forecast period 2026-2034, showcasing the fastest-growing regional market, while a 2025 IARC analysis projects global female breast cancer cases to reach 3.2 million annually by 2050, with the future burden expected to increase substantially across Asia and other lower-HDI settings.
The Japan breast biopsy market is supported by long-term cancer-incidence projections through 2039, while the China breast biopsy market is expected to face the largest absolute breast cancer case burden among the major countries by 2050; the South Korea breast biopsy market is supported by breast cancer remaining the leading cancer among Korean women, and the India breast biopsy market is expected to experience the largest increase in breast cancer cases among the countries examined in the 2025 IARC analysis.
The Europe breast biopsy market accounted for a regional share of 28.4% in 2025, while a 2026 European analysis projects Germany, France, and other major European countries to carry a substantial breast cancer burden by 2050, reinforcing the long-term need for diagnostic and biopsy services.
The U.K. breast biopsy market is supported by projections of around 70,300 new breast cancer cases annually by 2038-2040, while the Germany breast biopsy market and France breast biopsy market are expected to remain among the European countries with the highest breast cancer burden by 2050.
The breast biopsy market is moderately fragmented, with global medical-device manufacturers, breast-imaging companies, biopsy-system specialists, surgical-device manufacturers, and regional medical-device suppliers competing across core needle, vacuum-assisted, stereotactic, ultrasound-guided, and MRI-guided biopsy procedures. Hologic, Inc., Danaher Corporation, Becton, Dickinson and Company, Merit Medical Systems, Inc., and GE HealthCare are among the leading players in the breast biopsy market, collectively accounting for an estimated 45-50% of the global market share.
Established players compete primarily on diagnostic accuracy, device reliability, product portfolio, imaging compatibility, clinical performance, and distribution networks, while emerging players in the breast biopsy market ecosystem compete through compact device designs, improved ergonomics, procedure efficiency, specialized biopsy solutions, and technology integration. The presence of established systems from companies such as Hologic and BD reflects competition around multimodality compatibility, sample quality, workflow efficiency, and patient experience.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Radiosurgery Market Size, Share, Growth, Analysis, Report, 2034
Interventional Cardiology Devices Market Size, Share, Growth, 2034
Smart Inhalers Market Size, Share, Growth, Analysis, Report, 2034
Irradiation Apparatus Market Size, Share, Growth, Analysis, 2034
ECG Patch and Holter Monitor Market Size, Share, Growth, 2034
Dermatology Excimer Laser Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com